We have been steadily growing our global Injectables business through a combination of strategic acquisitions, expansion of manufacturing capabilities and investment in R&D.
Hikma has grown to become a top three US supplier of generic injectable medicines.1
In June 2024, following discussions with management, the Board approved the acquisition of Xellia Pharmaceuticals’ US finished dosage form business. This included a commercial portfolio and pipeline of differentiated products, a manufacturing facility in Bedford, Ohio, sales and marketing capabilities, and an R&D centre in Zagreb, Croatia.
Once the Bedford facility is fully operational after refurbishment, this acquisition will significantly expand our US Injectables manufacturing capacity and will add complex manufacturing technologies. In addition, it helps enrich our portfolio and pipeline as well as improves our ability to serve the growing needs of hospitals, healthcare professionals, and patients.
1IQVIA MAT November 2024, generic injectable volumes by eaches, excluding branded generics and Becton Dickinson